Markets:

Overview

News

Currencies

International

Treasuries

ImmunityBio, Inc. - Common Stock (NQ:IBRX)

6.930 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Feb 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about ImmunityBio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX

February 03, 2026

From Pomerantz LLP

Via GlobeNewswire

ImmunityBio Launches Phase 2 Chemotherapy-Free CAR-NK Cell Therapy Trial with ANKTIVA® (ResQ215B) in Indolent Lymphomas

February 02, 2026

From ImmunityBio

Via Business Wire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc. - IBRX

January 27, 2026

From Pomerantz LLP

Via GlobeNewswire

$5 Stocks: NDRA, IBRX, MOVE, RVLY Drawing Attention Watch Now!

January 25, 2026

Via AB Newswire

ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy

January 23, 2026

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA® in BCG-Unresponsive Papillary Bladder Cancer

January 20, 2026

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Announces Durable Complete Response of 15 Months with a Chemotherapy-Free CD19 CAR-NK Cell Therapy in Waldenstrom Lymphoma

January 16, 2026

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Advances First-Line BCG Naive NMIBC Program with Enrollment Exceeding Expectations and Positive Interim Analysis for ANKTIVA® Plus BCG

January 16, 2026

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Reports Continued Execution and Sales Momentum With $113 Million of Preliminary Net Product Revenue—a 700% increase year-over-year

January 15, 2026

From ImmunityBio, Inc.

Via Business Wire

MAGA SmallCaps Watchlist: ROLR, SURG, IBRX, BNAI, NDRA – January 2026 Focus

January 14, 2026

Via AB Newswire

Topics Derivatives

The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era

January 14, 2026

Issued on behalf of Oncolytics Biotech Inc.

From USA News Group

Via GlobeNewswire

Saudi FDA Grants Accelerated Approval to ImmunityBio’s ANKTIVA® In Combination with Checkpoint Inhibitors for Metastatic Non-Small Cell Lung Cancer

January 14, 2026

From ImmunityBio

Via Business Wire

Saudi FDA Grants Accelerated Approval to ImmunityBio’s ANKTIVA® for Non-Muscle Invasive Bladder Cancer with Carcinoma In-Situ

January 14, 2026

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Announces Positive Results Demonstrating ANKTIVA® as a Lymphocyte Stimulating Agent in Combination With Checkpoint Inhibitors in Non-Small Cell Lung Cancer

January 13, 2026

From ImmunityBio, Inc.

Via Business Wire

NantWorks and ImmunityBio Announce Inaugural U.S.-Saudi Biotech Alliance Summit to Advance Immunotherapy 2.0 and Global Health Security

January 12, 2026

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Founder Dr. Patrick Soon-Shiong Recognized as One of “100 Most Influential People in Oncology in 2025”

December 29, 2025

From ImmunityBio, Inc.

Via Business Wire

ANKTIVA® with BCG Demonstrates 96% Survival from Bladder Cancer at Three Years with Median Survival Not Yet Reached in BCG-Unresponsive High-Grade Papillary-Only Non-Muscle Invasive Bladder Cancer

December 16, 2025

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Receives Conditional Marketing Authorization Recommendation from the European Medicines Agency for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ—A First in Europe

December 12, 2025

From ImmunityBio

Via Business Wire

New Survey Reveals Non-Muscle Invasive Bladder Cancer Patients Seek More Care Conversations

November 13, 2025

From ImmunityBio, Inc.

Via Business Wire

Driven by Strong Demand, ImmunityBio Reports 467% Year-to-Date Unit Growth and $75 Million in Sales Year-to-Date, Up 434% from Q3 2024

November 04, 2025

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio’s ANKTIVA® Reverses Lymphopenia and Extends Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy

September 08, 2025

From ImmunityBio, Inc.

Via Business Wire

Initial Data Shows 100% Disease Control in 5 Out of 5 Patients With Recurrent Glioblastoma With Two Patients in Near Complete Response Treated With ImmunityBio’s ANKTIVA®, NK Cell Therapy Plus Optune Gio® Device

August 26, 2025

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Announces Phase 2 Study of ANKTIVA® in Patients with Long COVID

August 19, 2025

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Reports Complete Responses in Non-Hodgkin Waldenstrom Lymphoma Patients with Chemotherapy-Free, First-In-Class CD19 CAR-NK Immunotherapy

August 13, 2025

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Announces Houston’s Michael E. DeBakey VA Medical Center Is Among the First VA Hospitals to Administer ANKTIVA® to Bladder Cancer Patients

August 11, 2025

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Reports Q2 Earnings Release Reflecting 60% Increase in Revenue in Q2 2025, With Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-code

August 05, 2025

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio, Inc. Announces Execution of $80 Million Equity Financing from Multiple Institutional Investors

July 25, 2025

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Reports 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code with Regulatory Updates

July 25, 2025

From ImmunityBio, Inc.

Via Business Wire

Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers

July 09, 2025

Via Investor Brand Network

Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers

July 09, 2025

EQNX::TICKER_START (NYSE:CLDI),(NASDAQ:VRTX),(NASDAQ:IBRX),(NASDAQ:CRSP),(NASDAQ:CTMX) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Death

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Search Hotels in Sausalito

Find A Business

or Browse Listings

ImmunityBio, Inc. - Common Stock (NQ:IBRX)

Press Releases about ImmunityBio, Inc. - Common Stock